The First Trust RBA American Industrial Renaissance ETF (NYSEARCA:AIRR) delivered a 30% return in 2025, nearly doubling the S&P 500's 16% gain.

Berkshire Hathaway (BRK.A, BRK.B) will soon enter the Greg Abel era as CEO, with Warren Buffett remaining Chair to ensure continuity, as he hands over the reins to Abel. Recent Alphabet (GOOGL) purchase signals an interesting development, which also involved relatively high multiples, posting probing questions about who made that call? Key management changes, including departures of key lieutenants, raise questions about Abel's strategic direction in the post-Buffett era.

As PG&E pre-positions crews and other resources, the company reminds its customers to stay safe and be prepared for possible outages. OAKLAND, Calif.

Through employee giving, the dollar value of volunteer service and Duke Energy Foundation matching funds, more than $1 million was invested in the communities the company serves ST. PETERSBURG, Fla.

Coinbase said on Monday it will buy prediction markets startup The Clearing Company, as the crypto exchange looks to expand beyond its core digital assets business.

Both the FTEC and XLK ETFs have strong 1-, 3-, 5-, and 10-year performance track records. Both should be considered as core long-term diversified technology holdings in you portfolio. The top-5 holdings in both ETFs are NVIDIA, Apple, Microsoft, Broadcom, and Palantir. These companies are highly successful, are driving performance, and position the funds well for the future. XLK's focused portfolio (70 holdings vs. FTEC's 292) and larger AUM ($91.8B vs. $16.7B) provide greater scale and a more focused approach.

JOBY plans to double U.S. production capacity as demand for electric air taxis and federal support take flight.

Homebuilder stocks eye a 2026 rebound as easing mortgage rates, Fed cuts and improving sales signal recovery momentum.

AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.

Uber and Lyft will start testing Baidu's Apollo Go robotaxis in London in 2026, joining Waymo and local startup Wayve as companies that will have autonomous vehicles in the city next year.

Rivian Automotive ( NASDAQ:RIVN ) is betting its future on the R2, a midsize electric SUV scheduled to enter production in the first half of 2026.

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated's (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

America's favorite grocery ordering and delivery app came under pressure earlier this month after it was found to have engaged in numerous unlawful tactics that harmed shoppers and raised the cost of grocery shopping for Americans.

While artificial intelligence (AI) continues to dominate market headlines in 2025, many of the stocks most closely tied to the technology — the Magnificent 7 stocks of Alphabet ( NASDAQ:GOOG )( NASDAQ:GOOGL ), Amazon ( NASDAQ:AMZN ), Apple ( NASDAQ:AAPL ), Meta Platforms ( NASDAQ:META ), Microsoft ( NASDAQ:MSFT ), Nvidia ( NASDAQ:NVDA ), and Tesla ( NASDAQ:TSLA ) — have shown volatility or lagged.

SFBS, FULT, THFF and NWFL all lifted dividends recently, standing out as income plays amid cautious optimism.

LOS ANGELES, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Primo Brands Corporation (“Primo” or “the Company”) (NYSE: PRMB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the publicly traded securities of Primo Water Corporation ("Primo Water") between June 17, 2024 through November 8, 2024, inclusive, and/or (the publicly traded common stock of Primo Brands Corporation between November 11, 2024 through November 6, …

CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in …

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Dec. 22:

NEW YORK, NY / ACCESS Newswire / December 22, 2025 / For centuries, gold's value rested on weight, purity, and trust. In modern markets, those attributes are no longer sufficient on their own.